Comparative Analysis of Medicines Safety Advisories Released by Australia, Canada, the United States, and the United Kingdom-Reference-Cited by-同舟云学术

Comparative Analysis of Medicines Safety Advisories Released by Australia, Canada, the United States, and the United Kingdom

Published:2019-07-01 Issue:7 Volume:179 Page:982
ISSN:2168-6106
Container-title:JAMA Internal Medicine
language:en
Short-container-title:JAMA Intern Med

Author:

Perry Lucy T.¹,Bhasale Alice¹,Fabbri Alice¹,Lexchin Joel²,Puil Lorri³,Joarder Maisah¹,Mintzes Barbara¹

Affiliation:

1. Charles Perkins Centre and School of Pharmacy, Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia

2. School of Health Policy and Management, Faculty of Health, York University, Toronto, Ontario, Canada

3. Department of Anaesthesiology, Pharmacology, and Therapeutics, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada

Publisher

American Medical Association (AMA)

Subject

Internal Medicine

Link

http:///jamainternalmedicine/article-pdf/179/7/982/17690657/jamainternal_perry_2019_ld_190005.pdf

Reference4 articles.

1. Impact of FDA drug risk communications on health care utilization and health behaviors: a systematic review.;Dusetzina;Med Care,2012

2. Inconsistencies among European Union pharmaceutical regulator safety communications: a cross-country comparison.;Zeitoun;PLoS One,2014

3. A call for international harmonization in therapeutic risk management.;Hirst;Pharmacoepidemiol Drug Saf,2006

4. Communication of medical product risk: how effective is effective enough?;Goldman;Drug Saf,2004

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. An analysis of international strategies for monitoring and preventability described in medicinal product information: a study protocol;2024-06-15

2. Decision and timing of safety‐related labeling changes for new drugs in Japan: Comparison with the United States and the European Union;Pharmacoepidemiology and Drug Safety;2023-07-06

3. Regulatory judgments for toxicity signals of medicinal products: in search of accountability;BMJ;2022-11-03

4. Radical transparency in post-market oversight of medicine safety;BMJ;2022-10-05

5. Characterization and corroboration of safety signals identified from the US Food and Drug Administration Adverse Event Reporting System, 2008-19: cross sectional study;BMJ;2022-10-05